Introduction
The most common primary malignant tumor of the pleura is malignant mesothelioma (MPM). It has four major histological subtypes: epithelioid, sarcomatoid, desmoplastic, and biphasic (1) .
Mesothelioma appears to have a complex etiology in which environmental carcinogens (asbestos and erionite), ionizing radiation, dietary factors, viruses, and genetic factors act alone or in concert to cause malignancy (2, 3) . Current studies showed that lipid metabolism may have an important role in pathogenesis suggesting new targets for treatment of MPM (4) (5) (6) .
Alpha-methylacyl-CoA racemase (AMACR) is an intracellular enzyme that is involved in the beta-oxidation of branched fatty acids (7, 8) . There is increasing evidence showing that AMACR is a useful marker for many cancers of the prostate, liver, kidney, and colon (9) (10) (11) . However, the expression and clinical effects of AMACR in mesothelioma have not been researched yet. This study investigated AMACR expression and its correlation with clinical characteristics and survival of patients with MPM.
Materials and methods

Patients
The clinicopathologic characteristics of 71 patients who underwent a surgical resection for therapeutic and/or diagnostic approaches between June 2000 and June 2009 in our institute were reviewed retrospectively. In the preoperative evaluation, the results of a biochemistry panel including renal and liver function tests, alkaline phosphatase and serum calcium levels, complete blood count, posteroanterior chest radiographs, computed tomographic scans of the thorax including the upper abdomen, and bronchoscopy were obtained for all of the patients. The relationships between AMACR immunoreactivity and clinicopathologic factors, including Background/aim: Alpha-methylacyl-CoA racemase (AMACR), an intracellular enzyme involved in lipid metabolism, has emerged as an immunohistochemical marker for many types of cancer. Recent studies about the role of lipid metabolism in pathogenesis of mesothelioma have brought up some positive results. This study was conducted to investigate AMACR expression in the diagnosis of malignant pleural mesothelioma (MPM) and the correlation of this marker with clinical characteristics and survival.
age, sex, smoking history, histological type of tumor, pathologic T-N status, and stage were evaluated.
For correlating pathological findings with survival, patients who died due to postoperative mortality (1 patient) and patients whose date of death was unknown (17 patients) were all excluded. The remaining group comprised 53 patients.
The stage of each patient was evaluated according to the staging system of the International Mesothelioma Interest Group (IMIG), revised in 1995 (12).
Surgical procedure and treatment modality
The surgical procedures consisted of 36 video-assisted thoracic surgeries (VATS) (50.7%), 14 decortications (19.7%), 5 pleuropneumonectomies (7%), and 16 chest wall/pleural biopsies (22.5%). VATS and biopsies were performed for diagnostic approaches, whereas decortications and pleuropneumonectomies were for therapeutic approaches. The patient's performance status, stage of the disease, and the patient's own choices were considered in the choice of treatment modality. Treatment modalities applied to this group of patients were local radiotherapy (4 patients, 5.7%), chemotherapy with cisplatin and gemcitabine or pemetrexed (7 patients, 10%), local radiotherapy and chemotherapy (6 patients, 8.6%), pleuropneumonectomy (5 patients, 7.1%), decortication (7 patients, 10%), and decortication and radiotherapy and/or chemotherapy (6 patients, 8.6%). After diagnostic procedures, 35 patients (50%) did not receive any of these treatments due to their poor performance status or refusal of treatment.
Pathologic evaluation
All specimens were histologically reviewed by one pathologist and the most representative slides of tumors were selected. Immunohistochemistry was carried out on 5-µm-thick paraffin sections. Sections were dewaxed in a xylene substitute (Thermo Scientific, USA) and hydrated with a graded series of ethanol concentrations and water. Subsequently, antigen retrieval was obtained by boiling in 0.01 mol/L citrate buffer (pH 6.0) for 20 min in a microwave oven. Sections were incubated with primary antibody solution for rabbit monoclonal AMACR/ p504S (clone 13H4, Thermo Scientific) at a dilution of 1:100 for 30 min at room temperature. Immunostaining was performed with a streptavidin-biotin complex kit (Thermo Scientific). Diaminobenzidine was used as a chromogen. After incubation, chromogen specimens were counterstained with Harris hematoxylin and cover-slipped. Samples of prostate carcinoma were used as a positive control. Negative controls omitting the primary antibodies were also included.
The intensity of AMACR immunostaining was evaluated by light microscopy (Labophot 2; Nikon, Japan). Only cytoplasmic staining was considered. Intensity of staining was graded as 1+ weak, 2+ moderate, 3+ strong. Tumors without any staining were considered AMACR-negative (13) (Figure 1 ).
Statistical analyses
Pearson' s chi-squared test, Yates' chi-squared test, or Fisher' s exact test were used to compare differences among groups for categorical variables. The survival curves were estimated using the Kaplan-Meier method. Patient survival was expressed by using time zero as the date of pathologic diagnosis and death as the end point. The log-rank test was used for comparison of the survival curves in univariate analysis. In all the statistical analyses, P < 0.05 was considered statistically significant. All statistical analyses were performed by SPSS for Windows, version 15.0.
Results
The clinical and pathological characteristics of the patients are summarized in Table 1 . Positive staining was detected in 42.3% of the cases. The expression of AMACR according to histological subtypes is expressed in Table 2 .
Forty-two percent of 50 patients with epithelioid mesothelioma and 52.9% of 17 patients with biphasic mesothelioma were positive for AMACR immunostaining. Epitheloid sections were found to be AMACR-positive in four patients with biphasic mesothelioma; in five patients, only sarcomatoid sections showed positive staining. The remaining 9 patients with biphasic mesothelioma were totally AMACR-negative. However, the patients with pure sarcomatoid (2 cases) and desmoplastic mesothelioma (2 cases) were AMACR-negative. 
A1
A2 A3 As shown in Table 3 , AMACR expression and clinicopathologic factors, including age, sex, smoking history, pathologic T-N status, and stage, did not show a statistically significant correlation (P > 0.05).
In a previous study of our clinic we had explored AMACR immunoreactivity in adenocarcinoma and squamous cell carcinoma of the lung (14) . When we compared our results with the results of the adenocarcinoma group (73 cases) in the previous study, we found that AMACR immunoreactivity was observed more frequently in adenocarcinoma group than in the MPM group (P = 0.046). The specificity and sensitivity of AMACR immunostaining in detecting MPM were 42.3% and 41.1%, respectively.
After the patients were excluded according to the criteria mentioned above, data from remaining 53 patients were evaluated for survival analysis. The median survival for the AMACR-negative group was 13 ± 3.65 months whereas it was 16 ± 5.96 months for the AMACR-positive group. Although survival lines on the graph seem to be parallel, we could not show a statistically significant effect of AMACR on survival (P = 0.190, log-rank). In a larger group of patients the results may be statistically significant.
We performed Cox regression analysis to reveal the effect of age, sex, history of smoking, N status, stage, therapy modality, histological subtype, and AMACR immunoreactivity on overall survival (Table 4) .
N status was proven to have a statistically significant effect on overall survival of patients with MPM (P = 0.001). However, we could not show prognostic value of the other variables (P > 0.05).
Discussion
MPM is an important threat to public health, especially in regions with environmental exposure to asbestos. The pathologic differential diagnosis of MPM depends on electron microscopic, histochemical, and immunohistochemical studies. However, none of these methods are 100% specific (1) 
AMACR is an intracellular enzyme that is bimodally distributed to both the peroxisome and the mitochondrion. It has an important role in the beta-oxidation of branched fatty acids, bile acid intermediates, and metabolism of ibuprofen (7, 8) .
This enzyme takes a part in beta-oxidation of phytanic acid and pristanic acid. These branched chain fatty acids are naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-α). PPAR-α is one of the nuclear receptor proteins that has an important role in cellular differentiation, evolution, and metabolism (8) . The enhancement of PPAR-γ activity with its ligands, and the suppression of PPAR-α with its inhibitors, may prevent the formation of lung tumors, as well as accelerate lung cancer therapy (9) . Therefore, it is hypothesized that AMACR, which plays a role in the metabolism of the ligands of these nuclear receptors, may affect the pathogenesis and prognosis of cancer. Reactive oxygen radicals formed by beta-oxidation of branched chain fatty acids may also contribute to DNA damage in carcinogenesis. An alternative hypothesis would suggest that AMACR is overexpressed in the development of cancer, perhaps playing an important role in providing energy for the neoplastic cells. As the tumors become dedifferentiated, they no longer require these sources of energy.
AMACR overexpression was first proven to be an important diagnostic marker for prostate carcinoma, but recent studies showed that it is overexpressed in several cancers, including colorectal carcinomas, papillary renal cell carcinomas, hepatocellular carcinomas, melanoma, lymphoma, and endometrium, lung, breast, bladder, and sebaceous neoplasms (9) (10) (11) (15) (16) (17) (18) (19) (20) (21) . AMACR is also overexpressed in precursor lesions like high-grade prostatic intraepithelial neoplasia and colonic adenomas (18) , but there is a limited number of studies reporting on AMACR expression in lung cancer (9, 11, 13, 18 (11, 18) . The main cause of this contradiction is the type of antibody used in these studies. In the study by Zhou et al., a polyclonal antibody was used but Jiang et al.
used a monoclonal antibody. Nassar et al. found that only 14.3% of twenty-eight specimens with lung cancer were positive for AMACR, where only moderate and strong staining was considered as positive (9) . However, this is the first study about the expression and clinical effects of AMACR in mesothelioma. In our study, we used a monoclonal antibody and considered weak staining as positive, which resulted in 42.3% positive staining in all patients. However, we observed that the expression of AMACR differs according to histological subtypes. Epithelioid and biphasic mesothelioma had AMACR immunoreactivity rates of 42% and 52.9%, respectively, whereas the patients with pure sarcomatoid and desmoplastic mesothelioma were totally AMACRnegative. Additionally, sarcomatoid sections showed positive staining in only five of the patients with biphasic histology. We recommend that AMACR immunoreactivity in the differential diagnosis of sarcomatoid and desmoplastic mesothelioma must be further researched. The differential diagnosis of MPM from metastatic neoplasms of pleura, especially adenocarcinoma of lung, is one of the most common dilemmas of thoracic pathology. A definitive diagnosis of MPM requires a pathologic workup including immunohistochemistry. Positive carcinoma markers recommended for adenocarcinoma are thyroid transcription factor 1, carcinoembryonic antigen, LeuM1(CD15), Ber-Ep4, B72.3, HMFG-2, MOC31, and BG8 (Lewis Y ). There is an increasing interest in defining positive mesothelioma markers. Positive mesothelioma markers recommended recently include WT-1 protein, keratin 5/6, podoplanin (D2-40), HBM1, thrombomodulin, and calretinin (22, 23) .
In a previous study, which included 73 patients with adenocarcinoma and 69 patients with squamous cell carcinoma of the lung, the positive AMACRimmunoreactivity for each group was 59% and 42%, respectively (14) . When we compared our results with the results of the adenocarcinoma group in the previous study, we found that AMACR immunoreactivity was observed more frequently in the adenocarcinoma group than in the MPM group (P = 0.046). The specificity and sensitivity of AMACR immunostaining in detecting MPM were 42.3% and 41.1%, respectively. The minimum sensitivity of an immunohistochemical marker recommended for clinical use must be at least 80% (23) . The specificity and sensitivity of AMACR immunostaining in detecting MPM were not sufficient enough to recommend AMACR alone as a diagnostic tool in differential diagnosis.
The pattern of immunohistochemical staining is also important with certain antibodies; calretinin requires both cytoplasmic and nuclear staining to support a diagnosis of mesothelioma, while WT-1 should be only nuclear (23) . The pattern of immunohistochemical staining for AMACR is characterized by fine granular cytoplasmic staining due to its localization in the peroxisome and the mitochondrion. This pattern is easy to recognize but in some studies about prostate carcinoma weak staining was accepted as negative because some benign prostate lesions show weak staining with AMACR (13) . This is logical, especially if a polyclonal antibody was used for minimizing false positive results. However, due to studies showing that AMACR immunoreactivity does not exist in alveolar parenchyma (9, 11, 13) and the monoclonal antibody used in this study, we considered a weak staining pattern to be positive. Immunohistochemical markers also serve as prognostic indicators. A tissue-specific effect of AMACR immunoreactivity on degree of differentiation in colon, breast, and bladder carcinomas was revealed by some studies (24, 25) . The results of our study did not indicate any correlations with the clinicopathologic factors including age, sex, pathologic T status, therapy modality, or histological subtype or stage (P > 0.05). However, in Cox regression analysis, N status was proven to have a statistically significant effect on overall survival of patients with MPM (P = 0.001). This result emphasizes the prognostic significance of lymph node involvement in the IMIG staging system for MPM. It was found that treatment modalities used for this group of patients did not affect the overall survival of patients. We think this may be a good clue when it comes to researching new therapy modalities for this challenging disease. Recent efforts in multimodality treatment include treatment of a symptomatic malignant pleural effusion through an indwelling pleural catheter, systemic treatment with targeted agents, addition of monoclonal antibodies to a standard chemotherapy backbone, new techniques in radiation therapy, pleural intensity-modulated radiotherapy, helical tomography, and proton therapy (26) . We may support these efforts by encouraging our patients to participate in these clinical trials.
In a study by Shilo et al., low-intensity staining in small-cell carcinoma of lung in stages I and II was associated with worse patient outcome (13) . AMACR immunoreactivity may be more intense in metabolically active cells. Therefore, AMACR-positive groups might show better response to chemotherapy, which may result in better prognosis for AMACR-positive groups. Similar to these studies, the median survival of the AMACR-positive group in our study was better than that of the AMACRnegative group (16 and 13 months, respectively), but this correlation could not be proven statistically through overall survival analysis (P = 0.190). We think that the relatively small number of patients included in this analysis and the heterogeneity of our group in terms of performance status and other prognostic factors might cause these statistically nonsignificant results in survival analysis.
In conclusion, AMACR alone cannot be used as a diagnostic tool in the differential diagnosis of MPM, but we recommend that the effect of AMACR expression on survival and response to chemotherapy be further investigated in large-scale studies with a more homogeneous study population.
